Will Regeneron keep CV reps if drug goes away?

Quote
anonymous said:
I think DR said he leaves in June.
There's 2 separate but connected issues. The patent challenge may cost $500M and multiple years to win. If we don't get the injunction lifted by 2/21 then we have nothing to sell.
The REGN hospital team is a guide for how they will handle us peons. Vetted like Presidential candidates yet their jobs changed 2-3 times since hire, counting the ones who survived the purges. True, they actually kept about half that team of 60 in other roles. But that included moves to RA and derm teams, which have been filled. Think they had 60-90 days to post & interview inside REGN and then 2 mths severance. That would be the best case scenario.
We have a lot more people affected - maybe 200 all at once vs. 60. And again, the fallback slots have been taken. Yes I know the RA ppl have been sitting at home since Oct, but they're launching before Jun. Same with Derm.
The conf call we had with Legal last week - I appreciate some limited transparency, albeit 3 VERY long weeks after it all hit the fan. I understand the time lines better now, but no one should have left that call feeling confident about overturning the injunction.
I believe we actually sold over $100M in 2016 through Q3. But the Alliance spends like $5 for every $1 they bring in. So you have to wonder: is the Alliance leadership team or REGN board going to want to spend so much money on promotion, or cut the Commercial budget and re-invest in R&D? Eylea won't make tons of money forever... maybe starting in 2017.
If it's been a while since you sold in a pod, this is the worst of that experience. Our average patient age in clinical trials is 63... but we fund only a fraction of the necessary Foundation money for Med D patients. SNFI reps believe the promises of every "dude" working for an SP, send them all their business, and wonder why they can't see the script and why NRx and TRx are going sideways. SNFI blames REGN for the crappy Hub rollout, but they forget they negotiated the contracts with the SPs and PBMs. SNFI wants activity & metrics, like that matters with a specialty biologic market. How is this situation going to promote better collaboration & teamwork? Do people behave rationally when you're talking about losing their money?
SNFI PCP reps are in limbo with their territories, I'm hearing they won't have permanent assignments until March. My guess is SNFI is taking a "wait and see" approach. If the injunction doesn't get lifted, I could see SNFI CEO going to Len with the pitch of "Look, you guys are good with making cool stuff and not so solid on bringing products to market. Why don't you focus on your competencies, and let us focus on ours? Cut your Commercial team, we have reps with endo and now direct Praluent experience." That would explain why SNFI never wanted to move away from "total dirt", since they see tons of opportunity in IM and PCP even though we are beating AMGN with specialists.
Final thought - I've talked to recruiters who tell me some of the sales leaders who have told us "business as usual, we'll be fine" are calling those same recruiters.
I believe if you're not looking for something outside REGN, you should be. But what do I know? I came over here thinking my stock options would be worth something someday.
Click to expand...

Thanks for your over-explanation fuck
 






Here's the other thing about keeping REGN reps... Here's a couple things I hadn't thought about before.
  1. REGN doesn't make final decisions about Commercial head count. All has to be approved by the other side of the Alliance. We have to fill out time cards because SNFI basically funds our salaries. Our IC plans have to be similar in incentives and ultimate payout. Our hospital reps felt the pain too - their jobs changed big time from when they were hired until when we launched, because SNFI had hospital reps too. Same thing with Federal and other Market Access roles.
  2. I think SNFI has rights to the NDC for Praluent. So they have significant decision-making authority on all things connected to the franchise. At this point, is that really a surprise?
 






Yes, Sanofi pays for 50% or R&D and responsible for commercial on Praluent, Dupi, Sari. By this time next year, anticipate Regeneron's reputation to sink lower than dirt. Some of the internal emails and communications with Sanofi's manufacturing indicate CLUSTERFUCKVILLE!
 












anonymous said:
hey listen up shit balls-i cant stand that pasty bitch. So get your facts straight. Quit acting like you know everything dick face.. Now beat it. And I don't mean from the conversation either Rosie
Click to expand...
Lighten up Francis. You seem a bit unhinged. Maybe you should go to your safe place and seek puppy dog therapy. Maybe Sanofi will hire you for their pc sales force once Regen kicks you to the curb. They hire rejects like you. You'll fit in nicely. Your finished. Buubye d-bag.
 






anonymous said:
Lighten up Francis. You seem a bit unhinged. Maybe you should go to your safe place and seek puppy dog therapy. Maybe Sanofi will hire you for their pc sales force once Regen kicks you to the curb. They hire rejects like you. You'll fit in nicely. Your finished. Buubye d-bag.
Click to expand...


Hey fuckface, Ive got some reject for you right here. Now open wide shit bag
 


















Unfortunately, mo decent offers yet. May be a long time. Regeneron probably won't give much severance. Unlikely any medical coverage. Its just going to suck. Starbucks, here I come!
 












anonymous said:
Mo decent offers yet? I wonder why shit for brains. Starbucks is right-it's perfect for you jack off
Click to expand...

Toxic Fucked Up Culture and Cheap. Does the Sr. Leadership even know how bad the culture is here? I think they buy their own bullshit that this place is wonderful. Starbucks may well have better benefits and certainly a better work environment.
 
























anonymous said:
the drug isn't going away
we're going to make it through this
Click to expand...
we have sold $115 mill since launch, year and 1/2 ago. We spent millions on a worthless voucher and millions on sales reps, managers, marketing support, etc. Maybe we get thru June. Then we fight all the way to Supreme Court. That's a lot of lawyer fees & court fees. Sounds like good money chasing bad money. Merck set a court precedent against Gilead that patent protection does matter. This doesn't look good folks. Can the medical community survive with only one PCSK9? PBMs see them as interchangeable and so do doctors. What's the harm in having one? Praluent doesn't have any more to offer than that of Rapatha. Our drug is not needed in the grand scheme of things. Just keeping it real here folks. Keeping it real.
 






Read the latest 10-K? Potential patent violations with Dupi.

Guessed it, we stole this one from Amgen, Genentech & friends, AGAIN!

We will need a law for serial patent thieves called, Len's Law. Minimum 20 years to life in prison.
 






anonymous said:
Read the latest 10-K? Potential patent violations with Dupi.

Guessed it, we stole this one from Amgen, Genentech & friends, AGAIN!

We will need a law for serial patent thieves called, Len's Law. Minimum 20 years to life in prison.
Click to expand...

Spot on. Dupi' patent was likely thieved by Len too. There was a Seeking Alpha update this weekend highlighting how fucked up Regeneron's alleged pipeline is...a fraud. Lots of money being wasted from big pharma commercial types like Bob T and DR. The spending is out of control. We are way to heavy with sales, marketing, market access and training people.
 
























Top Bottom
Back
Quote